Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 20, 2018
Pharmacy Choice - News - Over-the-Counter Drugs - September 20, 2018

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 20 of 20     Go To Page:

9/20/18 - Patronise Only Registered Drug Outlets to Avoid Quackery, PCN Advises Public
Following high rate of fake drugs in circulation, Drug Distribution Inspection Committee and Enforcement, an arm of the Pharmacists Council of Nigeria, has urged Nigerians to patronise only registered drugs outlets. Thus, the organisation has embarked on an enforcement campaign across the nation in fulfillment of the mandate of ensuring that minimu
9/19/18 - After OTC, Focus Should Be on Clinical Hearing Services, Says JAMA Article
Given that the Over-the-Counter (OTC) Hearing Aid Act of 2017 is now law and a new FDA class of OTC hearing aids will be established by the end of 2020, efforts should now focus on ensuring that older adults also have access to affordable hearing care services, write Nicholas Reed, Frank Lin, and Amber Willink, PhD, in the September 13 JAM
9/19/18 - Alliance Pharma plc (LON:APH) had its Add rating reiterated by Numis Securities
Analyst Ratings For Alliance Pharma plc (LON:APH) Today, Numis Securities reiterated its Add rating on Alliance Pharma plc (LON:APH). There are 1 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Alliance Pharma plc (LON:APH) is Buy with a consensus target price of GBX [?] The post A
9/19/18 - Alliance Pharma plc (LON:APH) had its Add rating reiterated by Numis Securities with a GBX 115 price target
Analyst Ratings For Alliance Pharma plc (LON:APH) Today, Numis Securities reiterated its Add rating on Alliance Pharma plc (LON:APH) with a price target of GBX 115. There are 1 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Alliance Pharma plc (LON:APH) is Buy [?] The post Allianc
9/19/18 - CHPA Submits Comments to FDA Regarding Innovative Approaches for Nonprescription Drugs
Today, the Consumer Healthcare Products Association issued the following statement upon submitting comments to the Food and Drug Administration regarding its draft guidance titled,' Innovative Approaches for Nonprescription Drug Products.'. 'CHPA is committed to empowering consumer self-care by expanding choice and availability of safe, effective,
9/19/18 - Sunovion Announces Health Canada Approval of Aptiom (eslicarbazepine acetate) as Adjunctive Therapy for the Treatment of Partial-Onset Seizures in Adolescents and Children Above Six Years of Age
Sunovion Pharmaceuticals Inc. today announced that Health Canada approved the Supplemental New Drug Submission to expand the indication for its antiepileptic drug Aptiom to include use as an adjunctive therapy for the treatment of partial-onset seizures in adolescents and children above six years of age who are not satisfactorily controlled with
9/17/18 - C3 International Introduces Idrasil: the First Standardized Form of Prescription Medical Cannabis in a Pill
C3 International, a biopharmaceutical company that has played a leadership role in the emerging cannabinoid therapeutics health sector, today officially announced the launch of its flagship Idrasil pain management pill. Idrasil is the first standardized form of medical cannabis. It offers all of the medicinal analgesic and therapeutic benef
9/17/18 - Patent Application Titled "Topical Avermectin Formulations And Methods For Elimination And Prophylaxis Of Susceptible And Treatment Resistant Strains...
Patent Application Titled "Topical Avermectin Formulations And Methods For Elimination And Prophylaxis Of Susceptible And Treatment Resistant Strains Of Head Lice" Published Online. By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent applicatio
9/17/18 - Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Imodium Multi-Symptom Relief
By a News Reporter-Staff News Editor at Pharma Business Week Perrigo Company plc announced that it has received final approval from the U.S. Food& Drug administration for the store brand over-the-counter equivalent of Imodium Multi-Symptom Relief. Retail sales for the last 12 months were approximately $62 million as measured by IRI.
9/17/18 - Researchers Submit Patent Application, "Novel Device", for Approval (USPTO 20180244451)
By a News Reporter-Staff News Editor at Pharma Business Week From Washington, D.C., NewsRx journalists report that a patent application by the inventors BUNCE, Martin; CHEN, Dan; SILVESTRI, Gabriella, filed on August 25, 2016, was made available online on August 30, 2018. The patent's assignee is Novartis Consumer Health S.A.. News editors obtain
9/17/18 - Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's global efforts to help assure product quality and transparency at foreign drug...
Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's global efforts to help assure product quality and transparency at foreign drug manufacturing facilities. By a News Reporter-Staff News Editor at Pharma Business Week Over the past 25 years, globalization of drug manufacturing has prompted the FDA to change its regulatory landsc
9/15/18 - Bill would help customers know lowest Rx prices
Many pharmacists are prohibited from telling customers that a prescription to treat diabetes or high blood pressure may cost only $8 out of pocket, instead of $20 through insurance coverage. This bill has passed the Senate and is now in front of the House. Contact your member of Congress to support the "Know the Lowest Price Act" drug bill.
9/15/18 - Odisha IMA welcomes ban on combination drugs [New Indian Express (India)]
Odisha chapter of Indian Medical Association said though the Centre had banned such drugs in 2016, it could not be implemented as pharmaceutical companies moved the Supreme Court. State president of IMA, Dr Santosh Kumar Mishra said the ban was waiting to be imposed on the combination drugs as those medicines lead to side effects than synergetic ef
9/15/18 - Positive Phase 3 Results Presented for Dupixent (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals, Inc. and Sanofi today presented detailed results from a pivotal Phase 3 trial showing Dupixent monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients with moderate-to-severe atopic dermatitis, whose disease was...
9/14/18 - Bausch Health Announces Resolution of XIFAXAN Intellectual Property Litigation
BRIDGEWATER- Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, which is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, together with Salix's licensors Cedars-Sinai Medical Center and Alfasigma SpA, have agreed to...
9/14/18 - BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer
MENLO PARK- BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, today announced the appointment of David S. Tierney, M.D., as its chief executive officer. Dr. Tierney was also appointed as a director to the board of directors of BioPharmX. David Tierney commented,' BioPharmX is on the threshold
9/13/18 - Global Insomnia Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts (2018-2026)
The global insomnia treatment drugs market was valued at US$ 2,689.6 million in 2017, and is expected to reach US$ 4,332.4 million by 2026, expanding at a CAGR of 5.5% from 2018 to 2026.. Currently North America is leading the regional segment for insomnia treatment drugs market. Asia Pacific is anticipated to exhibit steady growth during the forec
9/13/18 - Innomane Inc. Announces Health Canada Approval and Canadian Launch of Diaronex, an Over-The-Counter Herbal Remedy to Help Relieve Diarrhea
-Innomane Inc., a Canadian pharmaceutical company, announces today the Health Canada approval and Canadian launch of Diaronex , a natural and herbal remedy made from the herb Holarrhena, which is recognized by World Health Organization to help relieve diarrhea. Healthcare practitioners now have a new time-trusted, natural alternative to recommend
9/13/18 - Paragon BioTeck Reformulated FRESHKOTE, Prompting Eyevance Acquisition
Paragon BioTeck, a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies, recently completed the reformulation for the FRESHKOTE family of lubricant eye drops, purchased this week by Eyevance Pharmaceuticals. Physicians have already...
9/13/18 - Salix Announces U.S. Launch of PLENVU, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies
BRIDGEWATER- Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Bausch Health Companies Inc., and its partner Norgine B.V. today announced the U.S. launch and availability of PLENVU. 'When detected early,...
Articles(s): 1 - 20 of 20     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415